New options and perspectives for proteinuria management after kidney transplantation

Transplantation Reviews

Volumn 26, Issue 1, 2012, Pages 44-52

  Soler, María José ^a   Riera, Marta ^a   Gutierrez, Álex ^b   Pascual, Julio ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ATRASENTAN; AVOSENTAN; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; CALCITRIOL; ENDOTHELIN RECEPTOR ANTAGONIST; FG 3019; GLYCOSAMINOGLYCAN; IMATINIB; LOSARTAN; METHYLSULFONYLBENZAMIDE; OSTEOGENIC PROTEIN 1; PARICALCITOL; PENTOXIFYLLINE; PERINDOPRIL; PLACEBO; PROTEIN KINASE C INHIBITOR; RENIN INHIBITOR; RUBOXISTAURIN; SCATTER FACTOR; SITAXSENTAN; SMP 534; SULODEXIDE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DISEASE CONTROL; DISEASE COURSE; EDEMA; GLOMERULOSCLEROSIS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER INJURY; MACROALBUMINURIA; MEDICAL LITERATURE; NONHUMAN; PATIENT SELECTION; PERIPHERAL EDEMA; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 82955208467     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.07.006     Document Type: Review

References (98)

1. Amer H., Fidler M.E., Myslak M., et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007, 7:2748-2756.
2. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000, 11(Suppl 15):S1-86.
3. Barama A.A. Mechanisms and management of proteinuria in kidney transplant patients. Drugs 2008, 68(Suppl 1):33-39.
4. Remuzzi G., Benigni A., Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288-296.
5. Palmer B.F. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007, 27:287-293.
6. Sarafidis P.A., Bakris G.L. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 2006, 21:2366-2374.
7. Levey A.S., de Jong P.E., Coresh J., et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010.
8. Halimi J.M., Buchler M., Al-Najjar A., et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007, 7:618-625.
9. Amer H., Cosio F.G. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009, 20:2490-2492.
10. Feldman D.L., Jin L., Xuan H., et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130-136.
11. Kelly D.J., Zhang Y., Moe G., Naik G., Gilbert R.E. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50:2398-2404.
12. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
13. Persson F., Rossing P., Schjoedt K.J., et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008, 73:1419-1425.
14. Lopez V., Martin M., Cobelo C., et al. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc 2010, 42:2883-2885.
15. Soler M.J., Wysocki J., Ye M., Lloveras J., Kanwar Y., Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007, 72:614-623.
16. Wong D.W., Oudit G.Y., Reich H., et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007, 171:438-451.
17. Ye M., Wysocki J., William J., Soler M.J., Cokic I., Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006, 17:3067-3075.
18. Oudit G.Y., Liu G.C., Zhong J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010, 59:529-538.
19. Batlle D., Jose Soler M., Ye M. ACE2 and diabetes: ACE of ACEs?. Diabetes 2010, 59:2994-2996.
20. Li Y.C., Qiao G., Uskokovic M., Xiang W., Zheng W., Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004, 89-90:387-392.
21. Yuan W., Pan W., Kong J., et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007, 282:29821-29830.
22. Kong J., Li Y.C. Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol 2003, 285:R255-261.
23. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
24. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288:E125-132.
25. Zhang Z., Sun L., Wang Y., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73:163-171.
26. Agarwal R., Acharya M., Tian J., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005, 68:2823-2828.
27. Fishbane S., Chittineni H., Packman M., Dutka P., Ali N., Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009, 54:647-652.
28. Zhang Z., Zhang Y., Ning G., Deb D.K., Kong J., Li Y.C. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008, 105:15896-15901.
29. Kuhlmann A., Haas C.S., Gross M.L., et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286:F526-533.
30. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
31. Dhaun N., Goddard J., Kohan D.E., Pollock D.M., Schiffrin E.L., Webb D.J. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008, 52:452-459.
32. Inoue A., Yanagisawa M., Kimura S., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989, 86:2863-2867.
33. Barton M., Traupe T., Haudenschild C.C. Endothelin, hypercholesterolemia and atherosclerosis. Coron Artery Dis 2003, 14:477-490.
34. Makino A., Kamata K. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 1998, 123:1065-1072.
35. Yamauchi T., Ohnaka K., Takayanagi R., Umeda F., Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990, 267:16-18.
36. Miyauchi T., Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391-415.
37. Enoki T., Miwa S., Sakamoto A., et al. Functional coupling of ETA receptor with Ca(2+)-permeable nonselective cation channel in mouse fibroblasts and rabbit aortic smooth-muscle cells. J Cardiovasc Pharmacol 1995, 26(Suppl 3):S258-261.
38. Traupe T., Lang M., Goettsch W., et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002, 20:2239-2245.
39. Letizia C., Iannaccone A., Cerci S., et al. Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res 1997, 29:247-251.
40. Peppa-Patrikiou M., Dracopoulou M., Dacou-Voutetakis C. Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors. Metabolism 1998, 47:1408-1412.
41. Orisio S., Benigni A., Bruzzi I., et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993, 43:354-358.
42. Hocher B., Thone-Reineke C., Rohmeiss P., et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997, 99:1380-1389.
43. Benigni A., Remuzzi G. Endothelin antagonists. Lancet 1999, 353:133-138.
44. Brochu E., Lacasse S., Moreau C., et al. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 1999, 14:1881-1888.
45. Nabokov A., Amann K., Wagner J., Gehlen F., Munter K., Ritz E. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 1996, 11:514-520.
46. Wolf S.C., Brehm B.R., Gaschler F., et al. Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant 1999, 14(Suppl 4):29-30.
47. Wenzel R.R., Littke T., Kuranoff S., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009, 20:655-664.
48. Mann J.F., Green D., Jamerson K., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21:527-535.
49. Sarafidis P.A., Lasaridis A.N. Diabetic nephropathy: endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol 2010, 6:447-449.
50. Dhaun N., MacIntyre I.M., Kerr D., et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011, 57:772-779.
51. Kohan D.E., Pritchett Y., Molitch M., et al. Addition of atrasentan to Renin-Angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011, 22:763-772.
52. Chappell D., Jacob M., Rehm M., et al. Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx. Biol Chem 2008, 389:79-82.
53. Nieuwdorp M., van Haeften T.W., Gouverneur M.C., et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006, 55:480-486.
54. Nieuwdorp M., Mooij H.L., Kroon J., et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006, 55:1127-1132.
55. Singh A., Satchell S.C., Neal C.R., McKenzie E.A., Tooke J.E., Mathieson P.W. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 2007, 18:2885-2893.
56. Weiss R., Niecestro R., Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007, 67:2681-2696.
57. Blouza S., Dakhli S., Abid H., et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010, 23:415-424.
58. Chen Y.M., Ng Y.Y., Lin S.L., Chiang W.C., Lan H.Y., Tsai T.J. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004, 19:1106-1115.
59. Lin S.L., Chen R.H., Chen Y.M., Chiang W.C., Tsai T.J., Hsieh B.S. Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation. Mol Pharmacol 2003, 64:811-822.
60. Lin S.L., Chen Y.M., Chien C.T., Chiang W.C., Tsai C.C., Tsai T.J. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 2002, 13:2916-2929.
61. Han K.H., Han S.Y., Kim H.S., Kang Y.S., Cha D.R. Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy. Inflammation 2010, 33:137-143.
62. Navarro J.F., Milena F.J., Mora C., Leon C., Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006, 26:562-570.
63. Navarro J.F., Mora C., Muros M., Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005, 16:2119-2126.
64. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52:454-463.
65. Navarro-Gonzalez J.F., Muros M., Mora-Fernandez C., Herrera H., Meneses B., Garcia J. Pentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications 2010.
66. Chen Y.M., Lin S.L., Chiang W.C., Wu K.D., Tsai T.J. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006, 69:1410-1415.
67. Renke M., Tylicki L., Rutkowski P., et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease-placebo controlled, randomized, cross-over study. Acta Biochim Pol 2010, 57:119-123.
68. Shu K.H., Wu M.J., Chen C.H., Cheng C.H., Lian J.D., Lu Y.S. Effect of pentoxifylline on graft function of renal transplant recipients complicated with chronic allograft nephropathy. Clin Nephrol 2007, 67:157-163.
69. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem J 1998, 332(Pt 2):281-292.
70. Dempsey E.C., Newton A.C., Mochly-Rosen D., et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000, 279:L429-438.
71. Idris I., Gray S., Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001, 44:659-673.
72. Amiri F., Garcia R. Regulation of angiotensin II receptors and PKC isoforms by glucose in rat mesangial cells. Am J Physiol 1999, 276(5 Pt 2):F691-699.
73. Babazono T., Kapor-Drezgic J., Dlugosz J.A., Whiteside C. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. Diabetes 1998, 47:668-676.
74. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest Jul 1 1997, 100:115-126.
75. Meier M., King G.L. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med 2000, 5:173-185.
76. Kelly D.J., Zhang Y., Hepper C., et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003, 52:512-518.
77. Tuttle K.R., Bakris G.L., Toto R.D., McGill J.B., Hu K., Anderson P.W. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005, 28:2686-2690.
78. Matz M., Naik M., Mashreghi M.F., Glander P., Neumayer H.H., Budde K. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. Expert Opin Drug Metab Toxicol 2011, 7:103-113.
79. Decleves A.E., Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 2010, 6:371-380.
80. Sharma K., Deelman L., Madesh M., et al. Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol 2003, 285:F1258-1270.
81. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
82. Ziyadeh F.N., Hoffman B.B., Han D.C., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
83. Sugaru E., Nakagawa T., Ono-Kishino M., et al. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 2006, 290:F813-820.
84. Russo L.M., del Re E., Brown D., Lin H.Y. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 2007, 56:380-388.
85. Sakharova O.V., Taal M.W., Brenner B.M. Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens 2001, 10:727-738.
86. Guha M., Xu Z.G., Tung D., Lanting L., Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. Faseb J 2007, 21:3355-3368.
87. Adler S.G., Schwartz S., Williams M.E., et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010, 5:1420-1428.
88. Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 2002, 11:23-30.
89. Matsumoto K., Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001, 59:2023-2038.
90. Cruzado J.M., Lloberas N., Torras J., et al. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004, 53:1119-1127.
91. Kato T., Mizuno S., Nakamura T. Preservations of nephrin and synaptopodin by recombinant hepatocyte growth factor in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice. Nephrology (Carlton) 2011, 16:310-318.
92. Wang S., Chen Q., Simon T.C., et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003, 63:2037-2049.
93. Wang S., de Caestecker M., Kopp J., Mitu G., Lapage J., Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006, 17:2504-2512.
94. Akahori H., Ota T., Torita M., Ando H., Kaneko S., Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005, 314:514-521.
95. Huang Y., Border W.A., Yu L., Zhang J., Lawrence D.A., Noble N.A. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008, 19:329-338.
96. Lassila M., Jandeleit-Dahm K., Seah K.K., et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005, 16:363-373.
97. Brouard S., Le Bars A., Dufay A., et al. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int 2011.
98. Banon-Maneus E., Diekmann F., Carrascal M., et al. Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation 2010, 15:548-558.